Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
ESCORT-HU Extension: European Sickle Cell Disease Cohort – Hydroxyurea – Extension

As safety information pertaining to the long-term use of HU remains incomplete in spite of the first safety study (ESCORT-HU), an extension of the latter is proposed.

Locations

61 France site

5 Germany sites

4 French Guiana sites

4 Italy sites

2 Guadeloupe sites

2 Martinique sites

1 Greece site

Age

> 2 Years

LEARN MORE
A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)

The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab (5.

Locations

9 United States sites

9 Brazil sites

6 United Kingdom sites

5 Italy sites

5 Germany sites

5 Belgium sites

4 Spain sites

3 Netherlands sites

3 Colombia sites

3 Greece sites

3 France sites

3 India sites

2 Panama sites

2 Canada sites

2 Lebanon sites

2 Turkey sites

1 South Africa site

1 Kenya site

1 United Arab Emirates site

1 Finland site

1 Ghana site

1 Jordan site

1 Oman site

Age

> 12 Years

Phase

Phase 3

LEARN MORE
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease

This is a single-arm, open-label, multi-site, single-dose Phase 1/2 study in subjects with severe sickle cell disease (SCD).

Locations

8 United States sites

1 Belgium site

1 Canada site

1 Germany site

1 Italy site

1 United Kingdom site

Age

12 to 35 Years

Phase

Phase 1/Phase 2

LEARN MORE
Register Sichelzellkrankheit Der GPOH

Sickle cell disease is one of the most common hereditary diseases.

Locations

1 Germany site

Age

< 100 Years

Genotypes

HbSS, HbSC

LEARN MORE